Clinical Trial Update: A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of E7080 (lenvatinib) alone and with everolimus in unresectable/metastatic renal cell carcinoma after prior VEGF therapy; study completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• E7080 (lenvatinib)
• Everolimus (everolimus)

Snippet

Sponsor: Eisai Inc. | Conditions: Metastatic Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-27